Valence Labs Ups the Game: A ₹205 Crore State-of-the-Art API Unit in Punjab

Valence Labs Private Limited is set to establish a state-of-the-art Active Pharmaceutical Ingredients (API) manufacturing unit in Jansui, Patiala, Punjab, representing an investment of ₹205 crores. This project aims to meet the growing demand for high-quality pharmaceutical products while adhering to stringent quality and safety standards. With a production capacity of 3300 tonnes per annum (TPA) of API, the facility will play a crucial role in enhancing India's pharmaceutical manufacturing capabilities.

The manufacturing unit will feature advanced technology and equipment, ensuring efficient and reliable production processes. One of the key highlights of the project is its commitment to environmental sustainability. Valence Labs plans to treat 320 kiloliters of effluents per day, significantly reducing its environmental impact and ensuring compliance with regulatory standards. This reflects the company's dedication to responsible and eco-friendly manufacturing practices.

Strategically located in Jansui, Patiala, the manufacturing unit benefits from excellent connectivity to major transportation networks and industrial hubs. This strategic location provides easy access to raw materials, skilled labor, and distribution channels, facilitating smooth operations and efficient supply chain management. The project is expected to create employment opportunities and stimulate economic growth in the region.

The API manufacturing unit project underscores Valence Labs' commitment to innovation, quality, and customer satisfaction. By investing in cutting-edge technology and adhering to the highest industry standards, the company aims to become a preferred supplier of pharmaceutical ingredients globally. The project also aligns with the Indian government's initiatives to promote domestic manufacturing and reduce dependence on imports in the pharmaceutical sector.

News by Rahul Yelligetti